Bausch Health Announces 2024 Annual Meeting of Shareholder Results

Rhea-AI Summary

Bausch Health (NYSE:BHC, TSX:BHC) announced the results of its 2024 annual meeting of shareholders held on May 14, 2024. All 10 nominated directors were elected with Thomas J. Appio receiving 181,373,219 votes for and 10,918,741 votes withheld. Shareholders approved the compensation of the named executive officers, an amendment to the 2014 Omnibus Incentive Plan, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The final vote results will be reported to the U.S. SEC on Form 8-K and will be available on SEDAR and the company's website.

Positive

• All 10 nominated directors were successfully elected by shareholders.
• Shareholders approved the compensation for the company's named executive officers.
• Amendment to the 2014 Omnibus Incentive Plan was approved, increasing the number of shares authorized for issuance.
• PricewaterhouseCoopers LLP was appointed as the company's independent registered public accounting firm for another year.

Negative

• Significant broker non-votes, totaling 70,931,303, were recorded across all director elections.
• Brett M. Icahn and Robert N. Power received over 19 million votes withheld, the highest among the directors.
• The reliance on Section 602.1 of the TSX Company Manual indicates the company required exemptions for certain transactions.

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders.

Annual Meeting Results

The 10 directors nominated at the Company's 2024 annual meeting of shareholders held on May 14, 2024, were elected by a vote of the shareholders. The detailed results of the vote for the election of directors are set out below:

Name		For				Withheld				Broker Non-Votes
Thomas J. Appio			181,373,219				10,918,741				70,931,303
Christian A. Garcia			181,143,285				11,148,675				70,931,303
Brett M. Icahn			170,144,670				22,147,290				70,931,303
Sarah B. Kavanagh			180,316,464				11,975,496				70,931,303
Frank D. Lee			173,147,642				19,144,318				70,931,303
Steven D. Miller			177,700,669				14,591,291				70,931,303
Richard C. Mulligan, Ph.D.			175,256,854				17,035,106				70,931,303
John A. Paulson			179,422,691				12,869,269				70,931,303
Robert N. Power			173,228,670				19,063,290				70,931,303
Amy B. Wechsler, M.D.			181,626,477				10,665,483				70,931,303

At the annual meeting of shareholders, shareholders also approved, in a non-binding advisory vote, the compensation of the Company's named executive officers, an amendment to the Company's 2014 Omnibus Incentive Plan to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.

For the purposes of Toronto Stock Exchange (TSX) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR profile and on the Company's website at www.bauschhealth.com.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership of Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.

###

Investor Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll free)

Media Contact:
Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785

SOURCE: Bausch Health Companies Inc.

View the original press release on accesswire.com

FAQ

What were the results of Bausch Health's 2024 annual meeting of shareholders?

All 10 nominated directors were elected, and shareholders approved the executive compensation, an amendment to the 2014 Omnibus Incentive Plan, and the appointment of PricewaterhouseCoopers LLP.

How did the shareholders vote for Thomas J. Appio in Bausch Health's 2024 annual meeting?

Thomas J. Appio received 181,373,219 votes for and 10,918,741 votes withheld.

What amendment was approved at Bausch Health's 2024 annual meeting?

An amendment to the 2014 Omnibus Incentive Plan was approved, increasing the number of shares authorized for issuance.

Which firm was appointed as Bausch Health's independent registered public accounting firm in 2024?

PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm until the 2025 annual meeting of shareholders.

What is the significance of Section 602.1 of the TSX Company Manual for Bausch Health?

Bausch Health relied on Section 602.1 for exemptions regarding certain transactions as an inter-listed issuer on NYSE and TSX.

Where can the final vote results of Bausch Health's 2024 annual meeting be found?

The final vote results will be reported to the U.S. SEC on Form 8-K and made available on Bausch Health's SEDAR profile and website.